Medications for Alzheimer's Disease
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Alzheimer's Disease.
Found 8 Approved Drugs for Alzheimer's Disease
Memantine
Brand Names
Aricept, Donepezil, Namenda, Namzaric, Adlarity
Memantine
Brand Names
Aricept, Donepezil, Namenda, Namzaric, Adlarity
Form: Patch, Tablet, Kit, Capsule, Solution
Method of administration: Oral, Transdermal
FDA approval date: November 25, 1996
Classification: Cholinesterase Inhibitor
Donepezil hydrochloride is indicated for the treatment of dementia of the Alzheimer's type. Efficacy has been demonstrated in patients with mild, moderate, and severe Alzheimer's disease. Donepezil hydrochloride is an acetylcholinesterase inhibitor indicated for the treatment of dementia of the Alzheimer's type. Efficacy has been demonstrated in patients with mild, moderate, and severe Alzheimer's Disease ( 1 ).
Rivastigmine
Brand Names
Rivastigmine Transdermal, Exelon
Rivastigmine
Brand Names
Rivastigmine Transdermal, Exelon
Form: Patch, Capsule
Method of administration: Oral, Transdermal
FDA approval date: July 06, 2007
Classification: Cholinesterase Inhibitor
EXELON PATCH is an acetylcholinesterase inhibitor indicated for treatment of: Mild, moderate, and severe dementia of the Alzheimer’s type (AD).
Amyvid
Generic Name
Florbetapir
Amyvid
Generic Name
Florbetapir
Form: Injection
Method of administration: Intravenous
FDA approval date: June 01, 2012
Classification: Radioactive Diagnostic Agent
AMYVID is indicated for positron emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for: Evaluation of Alzheimer's disease (AD) and other causes of cognitive decline Selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing information of the therapeutic products AMYVID is a radioactive diagnostic drug indicated for positron emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for: Evaluation of Alzheimer's disease (AD) and other causes of cognitive decline Selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing information of the therapeutic products ( 1 )
Leqembi
Generic Name
Lecanemab
Leqembi
Generic Name
Lecanemab
Form: Injection
Method of administration: Intravenous
FDA approval date: January 06, 2023
Classification: Amyloid Beta-directed Antibody
LEQEMBI is indicated for the treatment of Alzheimer’s disease. Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. LEQEMBI is an amyloid beta-directed antibody indicated for the treatment of Alzheimer’s disease. Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. ( 1 )
Rexulti
Generic Name
Brexpiprazole
Rexulti
Generic Name
Brexpiprazole
Form: Tablet, Kit
Method of administration: Oral
FDA approval date: July 10, 2015
Classification: Atypical Antipsychotic
Brexpiprazole tablets are indicated for: Adjunctive treatment of major depressive disorder (MDD) in adults. Treatment of schizophrenia in adults. Brexpiprazole tablets is an atypical antipsychotic indicated for: Use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults ( 1, 1.
Showing 1-5 of 8
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances